Modern hepatoprotection: a narrative review of existing approaches and prospects for the use of biotechnological drugs
Open Access
- 25 September 2023
- journal article
- review article
- Published by Zaporizhzhia State Medical and Pharmaceutical University in Modern medical technology
- No. 3,p. 58-65
Abstract
The prevalence of acute and chronic liver diseases is increasing worldwide, which affects the quality of life and can lead to dangerous, life-threatening complications. Almost 50.0 % of all cases of acute liver failure are caused by drugs, and the overall mortality due to drug-induced liver injury reaches 5.0–11.9 %. In 2020, the hospital incidence of diseases of the digestive organs in Ukraine amounted to 430,593 cases among the adult population, of which 11,976 were fatal. The aim of the study: to characterize modern approaches to hepatoprotection and prospects of biological therapy based on data from open sources of information. Materials and methods. Publications were selected based on the PubMed, ClinicalKey Elsevier, Cochrane Library, eBook Business Collection, and Google Scholar databases, which covered information about modern approaches to the treatment of liver diseases. Results. Patients with chronic liver disease are at risk of extrahepatic complications related to liver cirrhosis and portal hypertension, as well as organ-specific complications of certain liver diseases. These complications can impair the quality of life and increase morbidity and mortality before and after liver transplantation. With chronic damage to the liver by toxic substances, the development of fatty dystrophy against the background of connective tissue changes in the form of nonspecific reactive hepatitis is more often observed. Hepatoprotectors are a pharmacotherapeutic group of heterogeneous drugs that prevent the destruction of cell membranes and stimulate the regeneration of hepatocytes. According to the Anatomical Therapeutic and Chemical classification of drugs (ATC classification), hepatoprotectors take their place in the group of drugs affecting the digestive system and metabolism (A), intended for the treatment of diseases of the liver and biliary tract (A05). One of the promising directions of biological therapy in patients with liver pathology is the use of means obtained from the fetoplacental complex. Conclusions. Cell therapy in clinically significant volumes is an actual area of modern hepatology. The most promising directions of biological therapy in clinical hepatology are the use of mesenchymal stem cells, agents obtained from the fetoplacental complex, and gene therapy.Keywords
This publication has 53 references indexed in Scilit:
- The Epidemiology of Cirrhosis in the United StatesJournal of Clinical Gastroenterology, 2015
- Exploiting the unique regenerative capacity of the liver to underpin cell and gene therapy strategies for genetic and acquired liver diseaseThe International Journal of Biochemistry & Cell Biology, 2014
- Stem/Progenitor Cells in Liver Development, Homeostasis, Regeneration, and ReprogrammingCell Stem Cell, 2014
- Exosomes Derived from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Liver FibrosisStem Cells and Development, 2012
- Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infectionGut, 2011
- Mortality related to chronic hepatitis B and chronic hepatitis C in France: Evidence for the role of HIV coinfection and alcohol consumptionJournal of Hepatology, 2008
- Induction of Pluripotent Stem Cells from Mouse Embryonic and Adult Fibroblast Cultures by Defined FactorsCell, 2006
- Factors predisposing to peptic ulcer disease in asymptomatic cirrhotic patientsAlimentary Pharmacology & Therapeutics, 2005
- Upper Digestive Bleeding in Cirrhosis. Post–Therapeutic Outcome and Prognostic IndicatorsHepatology, 2003
- A NEW METHOD FOR THE PRODUCTION OF CHRONIC GASTRIC ULCER IN RATS AND THE EFFECT OF SEVERAL DRUGS ON ITS HEALINGJapanese Journal of Pharmacology, 1969